05657nam 2200685 450 991081505250332120200520144314.01-118-77816-21-118-77815-4(CKB)2550000001256706(EBL)1662193(OCoLC)857664391(MiAaPQ)EBC1662193(Au-PeEL)EBL1662193(CaPaEBR)ebr10856828(CaONFJC)MIL588429(PPN)194568741(EXLCZ)99255000000125670620140415h20142014 uy 0engur|n|---|||||rdacontentrdamediardacarrierCollaborative innovation in drug discovery strategies for public and private partnerships /edited by Dr. Rathnam Chaguturu ; Nobel Laureate Ferid Murad, foreword ; contributors Khusru Asadullah [and sixty four others]Hoboken, New Jersey :Wiley,2014.©20141 online resource (760 p.)Wiley Series on Technologies for the Pharmaceutical IndustryDescription based upon print version of record.0-470-91737-7 1-306-57178-2 Includes bibliographical references at the end of each chapters and index.Cover; Title page; Copyright page; Dedication; Collaborative Drug Discovery Ethos; Contents; Foreword; Preface; About the Book; About the Editor; Contributors; Part I: Perspectives on Collaborative Innovation; 1: Productive Relationships in Research and Development between Government, Industry, and Universities; Universities, Government, and Industry: Historical Beginnings in Prussia; Refinement and Broad Adoption: the United States; Land Grants; Investments in Research; Intellectual Property; Impact on U.S. Economy; General Principles for Success; Governments; Universities; Industry2: Divided We FallChallenges; Collaboration Models; Examples of Successful Biomedical Collaborations; Biomarkers Consortium; Predictive Safety Testing Consortium; SNP and SAEC Consortia; Principles of Collaboration; Governance, Administration, and Autonomy; Human Factors; Conclusion; References; 3: Innovation: Open Source and Nonprofit Models in Drug Discovery; Why Do People Innovate?; How Do We Encourage Innovation?; Why Is Innovation Important?; Warnings Regarding Innovation in Drug Discovery; Open Source Models; Nonprofit Models; Recommendations; References4: The Changing Face of Innovation in Drug DiscoveryIntroduction; Core Objectives of the Drug Discovery Process; Major Innovations in Technology Have Advanced Drug Discovery; Target Identification and Target Validation; Hit Identification: The First Stage in Drug Hunting; Lead Optimization: A Field to Which Companies Must Commit Major Amounts of Human and Financial Resources; Preclinical Assessment: Select the First-in-Class and/or Best-in-Class Drug Candidate for Clinical Development; An Important Trend: Academic and Pharmaceutical Organizations Are Collaborating in Support of Drug DiscoveryFuture Perspectives: Where Is Innovation Leading?References; 5: Current Trends in Collaborative Drug Discovery and Strategies to De-Risk Precompetitive Initiatives; Pharmaceutical Industry's Perspective; Academia's Perspective; Open (Collaborative) Innovation: A New Business Model; Drug Discovery through Collaborations; Drug Discovery through Consortia; Drug Discovery through Repurposing Strategies; Probe Discovery in Public Domain; Effective Management of Academia-Pharma Collaborations; Concluding Remarks; References6: A Perspective on the Evolution of Collaborative Drug Discovery and Future ChallengesEvolution of Collaborative Drug Discovery; Challenges for Collaborative Drug Discovery; Conclusion; References; Part II: Governmental Initiatives Accelerate Precompetitive Collaboration; 7: The Value of University-Industry Partnerships; Guiding Principles for University-Industry Collaborations; The Johnson Continuum; Role of Cocreation: Companies, Government, and Universities; Maryland Industrial Partnerships (MIPS) Program; Funding for Collaborations with AcademiaNew Initiatives to Transform University-Industry CollaborationsCan academia save the pharmaceutical industry? The pharmaceutical industry is at a crossroads. The urgent need for novel therapies cannot stem the skyrocketing costs and plummeting productivity plaguing R&D, and many key products are facing patent expiration. Dr. Rathnam Chaguturu presents a case for collaboration between the pharmaceutical industry and academia that could reverse the industry's decline. Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships provides insight into the potential synergy of basing R&D in academia while leaving dWiley series on technologies for the pharmaceutical industry.Drug DiscoveryPublic-Private Sector PartnershipsDrug developmentPublic-private sector cooperationDrug Discovery.Public-Private Sector Partnerships.Drug development.Public-private sector cooperation.615.1/9Chaguturu RathnamFerid Murad Nobel LaureateAsadullah KhusruMiAaPQMiAaPQMiAaPQBOOK9910815052503321Collaborative innovation in drug discovery3977476UNINA